49.21 | 49.21 | 61.38 | 25.55 | 49.23 | 86.89 | 0.26 | 47.41 | |||
49.90 | 50.64 | 35.88 |
Myopenia, yes |
1.34 (0.38–5.54) | 0.664 | - | - | 0.32 (0.07–1.18) | 0.112 | - | - | 3.11 (0.85–15.08) | 0.112 | - | - |
Visceral obesity, yes |
2.54 (0.68–12.40) | 0.196 | - | - | 0.65 (0.18–2.13) | 0.49 | - | - | 3.61 (1.09–14.44) | 0.047 | - | - |
Myopenic obesity, yes |
0.01 (0.00–0.001) | 0.993 | - | - | 20090605.83 (0.00–NA) | 0.993 | - | - | 279.10 (0.00–NA) | 0.993 | - | - |
Myosteatosis, yes |
1.39 (0.39–5.76) | 0.626 | - | - | 2.17 (0.58–10.58) | 0.282 | - | - | 5.05 (1.39–24.41) | 0.023 | 4.63 (1.03–28.42) | 0.063 |
Cancer cachexia, yes |
0.68 (0.18–2.94) | 0.585 | - | - | 2.83 (0.76–10.59) | 0.117 | - | - | 0.95 (0.27–3.60) | 0.935 | - | - |
Body mass index, kg/m2 | 1.00 (0.89–1.14) | 0.992 | - | - | 0.94 (0.81–1.06) | 0.351 | - | - | 0.95 (0.27–3.60) | 0.935 | - | - |
Skeletal Muscle Area, HU | 1.00 (0.99–1.02) | 0.869 | - | - | 1.00 (0.98–1.01) | 0.679 | - | - | 1.00 (0.99–1.02) | 0.681 | - | - |
Skeletal Muscle Index, cm2/m2 | 1.00 (0.95–1.07) | 0.88 | - | - | 1.00 (0.95–1.06) | 0.909 | - | - | 1.04 (0.98–1.10) | 0.230 | - | - |
Muscle Radiation Attenuation, HU | 0.98 (0.92–1.04) | 0.526 | - | - | 0.99 (0.93–1.05) | 0.775 | - | - | 0.94 (0.88–1.00) | 0.076 | - | - |
SAT, cm2 | 1.00 (0.99–1.00) | 0.336 | - | - | 1.00 (0.99–1.00) | 0.48 | - | - | 1.00 (0.99–1.01) | 0.866 | - | - |
VAT, cm2 | 1.00 (1.00–1.01) | 0.769 | - | - | 1.00 (0.99–1.00) | 0.622 | - | - | 1.00 (1.00–1.01) | 0.205 | - | - |
VSR | 1.55 (0.53–5.51) | 0.456 | - | - | 1.09 (0.39–2.861) | 0.861 | - | - | 1.72 (0.66–5.19) | 0.292 | - | - |
High VSR |
2.50 (0.63–9.52) | 0.179 | - | - | 2.75 (0.63–19.26) | 0.224 | - | - | 6.19 (1.69–26.52) | 0.008 | 5.05 (1.08–29.74) | 0.05 |
Body fat, % | 0.96 (0.87–1.05) | 0.380 | - | - | 1.00 (0.92–1.09) | 0.962 | - | - | 1.00 (0.93–1.09) | 0.912 | - | - |
Lean Body Mass, kg | 1.01 (0.96–1.07) | 0.765 | - | - | 1.02 (0.97–1.08) | 0.381 | - | - | 1.02 (0.97–1.08) | 0.381 | - | - |
SATI, cm2/m2 | 0.99 (0.97–1.01) | 0.279 | - | - | 0.99 (0.97–1.01) | 0.344 | - | - | 1.00 (0.99–1.02) | 0.794 | - | - |
VATI, cm2/m2 | 1.00 (0.99–1.02) | 0.625 | - | - | 1.00 (0.98–1.01) | 0.706 | - | - | 1.01 (1.00–1.04) | 0.122 | - | - |
High SATI |
1.80 (0.52–6.25) | 0.346 | - | - | 0.90 (0.26–2.93) | 0.863 | - | - | 1.50 (0.49–4.81) | 0.481 | - | - |
High VATI |
0.49 (0.10–1.87) | 0.327 | - | - | 0.38 (0.08–1.44) | 0.184 | - | - | 2.83 (0.84–11.45) | 0.111 | - | - |
Age, years | 61.0 (46.0 – 67.0) |
Gender | |
Male | 34 (58.6%) |
Female | 24 (41.4%) |
ASA grade | |
1 | 9 (16%) |
2 | 30 (52%) |
3 | 16 (28%) |
4 | 3 (5.2%) |
Baseline albumin, g/L | 41.0 (34.2 – 45.0) |
Baseline C-reactive protein, mg/L | 13.5 (2.0 – 66.5) |
Neutrophil-lymphocyte ratio | 3.3 (2.1 – 4.7) |
Body Mass Index, kg/m2 | 26.0 (24.7 – 29.7) |
Nutritional team support before operation | 28(48.3%) |
Skeletal Muscle Area, cm2 | 45.5 (115.9 – 170.1) |
Visceral Fat Area, cm2 | 104.5 (53.6 – 168.7) |
Subcutaneous Adipose Tissue Area, cm2 | 167.9 (127.9 – 231.6) |
Total Fat Area, cm2 | 23.6 (19.8 – 29.1) |
Total Body Fat, % | 30.6 (26.8 – 32.4) |
Lean Body Mass, kg | 52.7 (50.0 – 57.2) |
Skeletal Muscle Index, cm2/m2 | 50.2 (44.0 – 55.6) |
Appendicular Skeletal Muscle Index, cm2/m2 | 6.70 (6.00 – 7.3) |
Myopenia based on estimated cut-off value for SMI |
18 (31.0%) |
Myopenia based on EWGSOP2 criteria for SMI | 19 (32.8%) |
Cancer cachexia | 13 (22.4%) |
Visceral obesity | 21 (36.2%) |
Myopenic obesity | 4 (6.9%) |
Myosteatosis |
37 (63.7%) |
Postoperative (90 day) complication rate | 37 (64%) |
Abdominal complication | 24 (41%) |
Systemic complication | 17 (29%) |
Abdominal and systemic complications | 5 (9.0%) |
Clavien-Dindo > IIIa | |
Yes | 17 (29%) |
No | 41 (71%) |
Comprehensive Complication Index | 20.92 (0.0–32.55) |
Histologic type | |
Liposarcoma | 35 (60%) |
Leiomyosarcoma | 9 (16%) |
Pleomorphic sarcoma | 1 (1.7%) |
Other | 13 (22%) |
Tumour size, cm | 20 (11–30) |
FNCLCC grade | |
1 | 15 (26%) |
2 | 11 (19%) |
3 | 23 (40%) |
Unknown | 9 (16%) |
Stage AJCC (8th edition) | |
1A | 1 (1.7%) |
1B | 23 (40%) |
3A | 6 (10%) |
3B | 28 (48%) |
Completeness of surgical resection | |
R0 | 47 (81%) |
R1/R2 | 11 (19%) |
Age, years | Median (IQR) | 66.0 (50.5–71.5) | 61.0 (46.0–64.8) | 0.236 |
Gender | Male | 11(57.9) | 23 (60.5) | 1 |
Female | 8(42.1) | 15 (39.5) | ||
ASA Grade, 2–3 |
1 | 3 (15.8) | 6 (15.8) | 1 |
2–3 | 16 (84.2) | 32 84.2) | ||
FNCLCC Grade | 1 | 5 (29.4) | 10 (32.3) | 0.547 |
2 | 5 (29.4) | 5 (16.1) | ||
3 | 7 (41.2) | 16 (51.6) | ||
(Missing) | 7 (18.4) | 2 (10.5) | ||
Tumour size, cm | Median (IQR) | 26.0 (20.5–34.0) | 17.5 (10.0–24.8) | 0.005 |
Clavien-Dindo > IIIa | Yes | 3 (15.8) | 14 (36.8) | 0.183 |
No | 16 (84.2) | 24 (63.2) | ||
Neutrophil-lymphocyte ratio | Median (IQR) | 3.9 (2.4–4.7) | 3.0 (2.1–4.7) | 0.504 |
Baseline albumin, g/L | Median (IQR) | 40.0 (32.0–42.5) | 43.0 (35.0–45.8) | 0.232 |
Baseline C-reactive protein, mg/L | Median (IQR) | 44.0 (7.5–99.5) | 6.0 (2.0–45.0) | 0.088 |
Haemoglobin level, g/L | Median (IQR) | 128.0 (101.5–136.5) | 132.5 (115.2–145.8) | 0.141 |
Preoperative radiotherapy | No | 19 (100.0) | 37 (97.4) | 1 |
Yes | 0 (0.0) | 1 (2.6) | ||
Resection status | R0 | 17 (89.5) | 29 (76.3) | 0.406 |
R1 | 2 (10.5) | 9 (23.7) | ||
Intraoperative blood loss, ml | Median (IQR) | 1300.0 (425.0–4100.0) | 1350.0 (500.0–2075.0) | 0.78 |
Stage AJCC, 8th edition | 1A–1B | 7 (36.8) | 17 (44.7) | 0.776 |
3A–3B | 12 (63.2) | 21 (55.3) | ||
Histology subtype | Pleomorphic | 1 (5.3) | 0 (0.0) | 0.184 |
Liposarcoma | 14 (73.7) | 21 (55.3) | ||
Leiomyosarcoma | 2 (10.5) | 6 (15.8) | ||
Other | 2 (10.5) | 11 (28.9) | ||
Nutrition team before surgery | Yes | 12 (63.2) | 16 (42.1) | 0.223 |
No | 7 (36.8) | 22 (57.9) | ||
Length of hospital stay, days | Median (IQR) | 20.0 (11.0–28.8) | 15.0 (11.5–27.0) | 0.593 |
Visceral obesity | Yes | 4 (21.1) | 16 (42.1) | 0.202 |
No | 15 (78.9) | 22 (57.9) | ||
Myosteatosis | Yes | 16 (84.2) | 21 (56.8) | 0.079 |
No | 3 (15.8) | 16 (43.2) | ||
Cancer cachexia | No | 12 (63.2) | 31 (83.8) | 0.163 |
Yes | 7 (36.8) | 6 (16.2) | ||
Body Mass Index, kg/m2 | Median (IQR) | 25.7 (23.3–27.2) | 26.9 (24.8–30.9) | 0.071 |
Skeletal Muscle Area, HU | Median (IQR) | 115.8 (106.5–153.3) | 149.9 (130.6–177.1) | 0.019 |
Skeletal Muscle Index, cm2/m2 | Median (IQR) | 41.0 (38.3–46.8) | 53.5 (46.2–58.8) | < 0.001 |
Muscle Radiation Attenuation, HU | Median (IQR) | 35.6 (31.8–43.2) | 38.1 (29.9–42.2) | 0.959 |
Subcutaneous Adipose Tissue Area, cm2 | Median (IQR) | 156.4 (103.2–194.4) | 185.4 (131.4–254.1) | 0.078 |
Visceral Adipose Tissue Area, cm2 | Median (IQR) | 64.6 (38.1–131.6) | 125.5 (66.1–201.7) | 0.07 |
Visceral-to-subcutaneous adipose tissue area ratio | Median (IQR) | 0.5 (0.2–0.9) | 0.8 (0.3–1.1) | 0.393 |
Body fat, % | Median (IQR) | 28.3 (21.3–31.6) | 31.1 (28.1–33.3) | 0.024 |
Lean Body Mass, kg | Median (IQR) | 52.5 (50.4–57.7) | 52.8 (49.8–56.4) | 0.684 |
Subcutaneous Adipose Tissue Index, cm2/m2 | Median (IQR) | 46.8 (30.6–67.2) | 64.6(43.9–95.0) | 0.048 |
Visceral Adipose Tissue Index, cm2/m2 | Median (IQR) | 20.6 (13.2–43.8) | 42.3 (24.2–63.6) | 0.025 |